Hollow fibre infection models are being developed to assess new antiviral compounds. Clinical protocols are being developed to test experimental therapies for COVID-19. Clinical trials are supported by GCP bioanalytical capabilites and PK-PD modelling. Prescribing resources to support clinical trials of experimental COVID therapies have been developed.